Cardiovascular effect of testosterone replacement therapy in aging male

Acta Biomedica

Volumn 81, Issue SUPPL. 1, 2010, Pages 101-106

  Francomano, Davide ^a   Bruzziches, Roberto ^a   Natali, Marco ^a   Aversa, Antonio ^a   Spera, Giovanni ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Atherosclerosis; Late onset hypogonadism; Metabolic syndrome

Indexed keywords

ANDROGEN; TESTOSTERONE;

AGING; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; HUMAN; HYPOGONADISM; MALE; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

AGING; ANDROGENS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; HYPOGONADISM; MALE; TESTOSTERONE;

EID: 77954911504     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Mohr BA, Guay AT, O'Donnell AB, McKinlay JB. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 2005; 62: 64-73.
2. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002; 87: 589-98.
3. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724-31.
4. Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl 2001; 22: 718-31.
5. Kshirsagar A, Seftel A, Ross L, Mohamed M, Niederberger C. Predicting hypogonadism in men based upon age, presence of erectile dysfunction, and depression. International Journal of Impotence Research 2006; 18: 47-51.
6. Kapoor D, Jones TH. Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention? Drugs Aging 2008; 25(5): 357-69.
7. Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009; 30: 10-22.
8. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and development of type 2 diabetes mellitus in older men and women: Rancho-Bernard study. Diabetes Care 2002; 25: 55-60.
9. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009; 30: 23-32.
10. Fukui M, Kitagawa Y, Ose H, Hasegawa G, Yoshikawa T, Nakamura N. Role of endogenous androgen against insulin resistance and athero-sclerosis in men with type 2 diabetes. Curr Diabetes Rev 2007; 3: 25-31.
11. Traish AM, Saad F, Feeley RJ, Guay AT. The Dark Side of Testosterone Deficiency: III. Cardiovascular Disease. J Androl 2009; 30: 477-94.
12. Stanworth RD, Kapoor D, Channer KS, Jones TH. Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care 2009; 32: 541-6.
13. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91:1305-1308.
14. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106: 581-8.
15. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effect of transdermal testosterone on cognitive function and healt perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2002; 57: M321-5.
16. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966-72.
17. Tan RS, Pu SJ. Impact of obesity on hypogonadism in the andropause. Int J Androl 2002; 25: 195-201.
18. Morales A, Heaton JP. Hormonal erectile dysfunction. Evaluation and management. Urol Clin North Am 2001; 28: 279-88.
19. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981; 53: 58-68.
20. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol 2006; 65: 275-81.
21. Amore M. Partial androgen deficiency and neuropsychiatric symptoms in aging men. J Endocrinol Invest 2005; 28: 49-54.
22. Cherrier MM. Androgens and cognitive function. J Endocrinol Invest 2005; 28: 65-75.
23. Carosa E, Volpe R, Martini P, et al. Psychosocial issues of ART in aging male. J Endocrinol Invest 2005; 28: 117-21.
24. [AHA] American Heart Association. Heart disease and stroke statistics. Dallas: American Heart Association, 2002.
25. MacKay JD, Mensah GA. The atlas of heart disease and stroke. Geneva: WHO, 2004
26. Alberti KG, Zimmet P, Shaw J. The MS-a new worldwide definition. Lancet 2005; 366: 1059-62.
27. Guzder NR, Gatling W, Mullee MA, Byrne CD. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia 2006; 49: 56-65.
28. Rodriguez A, Muller DC, Metter EJ, et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007; 9: 3568-72.
29. Simon D, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 1997; 82: 682-5.
30. Khaw K, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 2007; 116: 2694-701.
31. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906.
32. English K, Steeds R, Jones T, Diver M, Channer K. Lowdose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000; 102: 1906-11.
33. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003; 24: 183-217.
34. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 1999; 84: 813-9.
35. English KM, Jones RD, Jones TH, Morice AH, Channer KS. Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm Metab Res 2001; 33: 645-52.
36. Hanke H, Lenz C, Hess B, Spindler KD, Weidemann W. Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 2001; 103: 1382-5.
37. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999; 99: 1666-70.
38. Costarella CE, Stallone JN, Rutecki GW, Whittier FC. Testosterone causes direct relaxation of rat thoracic aorta. J Pharm Exp Ther 1996; 277: 34-9.
39. Perusquia M, Hernandez R, Morales MA, Campos MG, Villalon MG. Role of the endothelium in the vasodilating effect of progestins and androgens on the rat thoracic aorta. Gen Pharmacol 1996; 27: 181-5.
40. English KM, Jones RD, Jones TH, Morice AH, Channer KS. Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest 2002; 25: 455-8.
41. Tep-areenan P, Kendall DA, Randall MD. Testosteroneinduced vasorelaxation in the rat mesenteric arterial bed is mediated predominantly via potassium channels. Br J Pharmacol 2002; 135: 735-40.
42. Rosano GM, Leonardo F, Pagnotta P, et al. Acute antiischemic effect of testosterone in men with coronary artery disease. Circulation 1999; 99: 1666-70.
43. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004; 90: 871-6.
44. Fukui M, Kitagawa Y, Ose H, Hasegawa G, Yoshikawa T, Nakamura N. Role of endogenous androgen against insulin resistance and atherosclerosis in men with type 2 diabetes. Curr Diabetes Rev 2007; 3: 25-31.
45. Rosano GM, Sheiban I, Massaro R, et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 2007; 19: 176-82.
46. Akishita M, Hashimoto M, Ohike Y, et al. Low testosterone level is an independent determinant of EDys in men. Hypertens Res 2007; 30: 1029-34.
47. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 2003, 157:25-31.
48. Murakami S, Otsuka K, Hotta N, et al. Common carotid intima-media thickness is predictive of all-cause and cardiovascular mortality in elderly community-dwelling people: Longitudinal Investigation for the Longevity and Aging in Hokkaido County (LILAC) study. Biomed Pharmacother 2005, 59: S49-53.
49. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002; 87: 3632-9.
50. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 2004; 109: 2074-9.
51. Van Pottelbergh I, Braeckman L, De Bacquer D, De Backer G, Kaufman JM. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profi le in healthy middle-aged men. Atherosclerosis 2003; 166: 95-102.
52. Haffner SM, Mykkänen L, Valdez RA, Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993; 77: 1610-15.
53. Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profi le in middleaged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 280-93.
54. Fogari R, Preti P, Zoppi A, Fogari E, Rinaldi A, Corradi L. Serum testosterone levels and arterial blood pressure in the elderly. Hypertens Res 2005, 28:625-30.
55. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906.
56. Glueck CJ, Glueck HI, Stroop D, Speirs J, Hamer T, Tracy T. Endogenous testosterone, fi brinolysis, and coronary heart disease risk in hyperlipidemic men. J Lab Clin Med 1993; 122: 412-20.
57. Smith AM, English KM, Malkin CJ, Jones RD, Jones TH, Channer KS. Testosterone does not adversely affect fi brinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina. Eur J Endocrinol 2005; 152: 285-91
58. Anderson RA, Ludlam CA, Wu FC. Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemost 1995; 74:693-7.
59. Maggio M, Basaria S, Ble A, et al. Correlation between testosterone and the infl ammatory marker soluble interleukin-6 receptor in older men. J Clin Endocrinol Metab 2006; 91: 345-7.
60. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous infl ammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 3313-8.